Cargando…

Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly

BACKGROUND: The present study compared the effects of antifibrotic medications, pirfenidone, and nintedanib, with transplantation of human umbilical mesenchymal stem cells (HUMSCs) in restoring rat pulmonary fibrosis (PF). METHODS: A stable animal model was established via an intratracheal injection...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Kuo-An, Yeh, Chang-Ching, Kuo, Fu-Hsien, Lin, Wen-Ren, Hsu, Chien-Wei, Chen, Tien-Hua, Fu, Yu-Show
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702727/
https://www.ncbi.nlm.nih.gov/pubmed/33256831
http://dx.doi.org/10.1186/s13287-020-02012-y
_version_ 1783616602539819008
author Chu, Kuo-An
Yeh, Chang-Ching
Kuo, Fu-Hsien
Lin, Wen-Ren
Hsu, Chien-Wei
Chen, Tien-Hua
Fu, Yu-Show
author_facet Chu, Kuo-An
Yeh, Chang-Ching
Kuo, Fu-Hsien
Lin, Wen-Ren
Hsu, Chien-Wei
Chen, Tien-Hua
Fu, Yu-Show
author_sort Chu, Kuo-An
collection PubMed
description BACKGROUND: The present study compared the effects of antifibrotic medications, pirfenidone, and nintedanib, with transplantation of human umbilical mesenchymal stem cells (HUMSCs) in restoring rat pulmonary fibrosis (PF). METHODS: A stable animal model was established via an intratracheal injection of 5 mg bleomycin (BLM). One single transplantation of 2.5× 10(7) HUMSCs or initiation of daily oral nintedanib/pirfenidone administration was performed on day 21 following BLM damage. RESULTS: Pulmonary function examination revealed that BLM rats exhibited a significant decrease in blood oxygen saturation and an increase in respiratory rates. While no significant improvements were found in BLM rats receiving nintedanib or pirfenidone, those who transplanted with HUMSCs showed a statistical amelioration in blood oxygen saturation and significant alleviation in respiratory rates. Quantification results revealed that a significant reduction in alveolar space and marked increases in substantial cell infiltration and collagen deposition in the left lungs of BLM rats. No significant alteration was observed in BLM rats administered nintedanib or pirfenidone. However, BLM rats transplanted with HUMSCs had a significant recovery in alveolar space and noticeable decreases in cell infiltration and collagen deposition. The inflammatory cell numbers in the bronchoalveolar lavage was increased in the BLM group. While the rats treated with nintedanib or pirfenidone had a lower cell number than the BLM group, a higher cell number was found as compared with the Normal group. In rats transplanted with HUMSCs, the cell number did not differ from the Normal group. CONCLUSIONS: Transplantation of HUMSCs could effectively treat PF as opposed to the administration of anti-fibrotic drugs with nintedanib or pirfenidone with a significant better result in lung volume, pathological changes, lung function, and blood oxygen saturation.
format Online
Article
Text
id pubmed-7702727
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77027272020-12-01 Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly Chu, Kuo-An Yeh, Chang-Ching Kuo, Fu-Hsien Lin, Wen-Ren Hsu, Chien-Wei Chen, Tien-Hua Fu, Yu-Show Stem Cell Res Ther Research BACKGROUND: The present study compared the effects of antifibrotic medications, pirfenidone, and nintedanib, with transplantation of human umbilical mesenchymal stem cells (HUMSCs) in restoring rat pulmonary fibrosis (PF). METHODS: A stable animal model was established via an intratracheal injection of 5 mg bleomycin (BLM). One single transplantation of 2.5× 10(7) HUMSCs or initiation of daily oral nintedanib/pirfenidone administration was performed on day 21 following BLM damage. RESULTS: Pulmonary function examination revealed that BLM rats exhibited a significant decrease in blood oxygen saturation and an increase in respiratory rates. While no significant improvements were found in BLM rats receiving nintedanib or pirfenidone, those who transplanted with HUMSCs showed a statistical amelioration in blood oxygen saturation and significant alleviation in respiratory rates. Quantification results revealed that a significant reduction in alveolar space and marked increases in substantial cell infiltration and collagen deposition in the left lungs of BLM rats. No significant alteration was observed in BLM rats administered nintedanib or pirfenidone. However, BLM rats transplanted with HUMSCs had a significant recovery in alveolar space and noticeable decreases in cell infiltration and collagen deposition. The inflammatory cell numbers in the bronchoalveolar lavage was increased in the BLM group. While the rats treated with nintedanib or pirfenidone had a lower cell number than the BLM group, a higher cell number was found as compared with the Normal group. In rats transplanted with HUMSCs, the cell number did not differ from the Normal group. CONCLUSIONS: Transplantation of HUMSCs could effectively treat PF as opposed to the administration of anti-fibrotic drugs with nintedanib or pirfenidone with a significant better result in lung volume, pathological changes, lung function, and blood oxygen saturation. BioMed Central 2020-11-30 /pmc/articles/PMC7702727/ /pubmed/33256831 http://dx.doi.org/10.1186/s13287-020-02012-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chu, Kuo-An
Yeh, Chang-Ching
Kuo, Fu-Hsien
Lin, Wen-Ren
Hsu, Chien-Wei
Chen, Tien-Hua
Fu, Yu-Show
Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
title Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
title_full Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
title_fullStr Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
title_full_unstemmed Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
title_short Comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from Wharton’s jelly
title_sort comparison of reversal of rat pulmonary fibrosis of nintedanib, pirfenidone, and human umbilical mesenchymal stem cells from wharton’s jelly
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702727/
https://www.ncbi.nlm.nih.gov/pubmed/33256831
http://dx.doi.org/10.1186/s13287-020-02012-y
work_keys_str_mv AT chukuoan comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly
AT yehchangching comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly
AT kuofuhsien comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly
AT linwenren comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly
AT hsuchienwei comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly
AT chentienhua comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly
AT fuyushow comparisonofreversalofratpulmonaryfibrosisofnintedanibpirfenidoneandhumanumbilicalmesenchymalstemcellsfromwhartonsjelly